Loading...
Loading...
- JMP Securities raised the price target on Karuna Therapeutics Inc KRTX from $175 to $190 with a Market Outperform rating.
- The analysts note Karuna as the top pick ahead of imminent Phase 3 results for KarXT in schizophrenia.
- They note that results from the Phase 3 EMERGENT-2 trial are expected within weeks (estimated mid-July to mid-August), with high confidence levels (probability of success ~80%).
- "Looking ahead to KarXT's commercial potential, we believe that in addition to robust efficacy, differentiating attributes that can drive adoption are the novel mechanism of action and favorable safety/tolerability profile," JMP writes.
- Also See: Amid Russia's Invasion On Ukraine, Karuna Therapeutics Withdraws Guidance On Late-Stage Schizophrenia Trial.
- "We also believe that the opportunity for the candidate in additional indications, specifically ADP, remains underappreciated, and positive schizophrenia results should have broader positive read-through," it added.
- The increased price target reflects higher U.S. peak penetration sales in schizophrenia (from $1.9 billion in 2028 to around $2.5 billion in 2030) and an increased probability of approval in Alzheimer's disease psychosis (ADP) (from 50% to 60%).
- Price Action: KRTX shares closed up 2.45% at $120.65 on Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in